Document is current
Any future updates will be listed below
-
Authors
Etzerodt, Anders https://orcid.org/0000-0002-6757-2068
Mikkelsen, Jakob Hauge https://orcid.org/0000-0002-2914-3297
Torvund-Jensen, Morten
Hennig, Dorle https://orcid.org/0000-0002-3167-5524
Boesen, Thomas
Graversen, Jonas Heilskov https://orcid.org/0000-0001-7119-2108
Moestrup, Søren Kragh
Kollman, Justin M. https://orcid.org/0000-0002-0350-5827
Andersen, Christian Brix Folsted https://orcid.org/0000-0001-6182-2436
-
Funding
Funding for this research was provided by:
Lundbeckfonden (R291-2018-49)
Ragna Rask-Nielsens Grundforskningsfond Direktør Ib Henriksens Fond
Danmarks Grundforskningsfond (DNRF141)
- License Information
-
More Information
Article History
Received: 8 May 2024
Accepted: 2 December 2024
First Online: 30 December 2024
Competing interests
: A.E. and J.H.G. and S.K.M reports to be minority shareholders of OncoSpear ApS that develops CD163 antibodies for the treatment of cancer. The remaining authors declare no competing interests.
